A perspective on aprotinin

Annals of Pharmacotherapy

Volumn 30, Issue 4, 1996, Pages 407-408

  Cooper, Brad E ^a  

^a HAMOT MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APROTININ; HEMOSTATIC AGENT;

CLINICAL TRIAL; ECONOMICS; HEMOSTASIS; METHODOLOGY; NOTE; TREATMENT OUTCOME;

APROTININ; CLINICAL TRIALS; HEMOSTASIS, SURGICAL; HEMOSTATICS; TREATMENT OUTCOME;

EID: 0030122191     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000416     Document Type: Article

References (7)

1. Robert S, Wagner B, Boulanger M, Richer M. Aprotinin. Ann Pharmacother 1996;30:372-80.
2. Bidstrup BP, Harrison J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations: a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993;55:971-6.
3. Dietrich W, Barankay A, Hahnel CH, Richter JA, High-dose aprotinin in cardiac surgery: three years' experience in 1784 patients. J Cardiothorac Vasc Anesth 1992;6:324-7.
4. Cosgrove DM, Hcric B, Lytle BW, Taylor PC, Novoa R, Golding LA, et al. Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
5. Lemmer JH, Stanford W, Bonney SL, Breen JF, Chemka EV, Eldridge WJ, et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994;107:543-53.
6. Levy JH, Pifarre R, Schaff HV, Harrow JC, Albus R, Spiess B, et al. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. Circulation 1995;92:2236-44
7. Royston D. Intraoperative coronary thrombosis: can aprotinin be incriminated (editorial)? J Cardiothorac Vasc Anesth 1994;8:137-41.